The effect of usual dose rosuvastatin plus ezetimibe versus high-dose rosuvastatin on coronary atherosclerotic plaque: A randomized controlled trial

Samsung Medical Center0 个研究点目标入组 280 人开始时间: 待定最近更新: 2019年3月11日

适应症

试验速览

暂无简介。

•? Subject age 18 years old or more
•? Among patients who undergo coronary angiography for suspected ischemic heart disease and meet all of the followings:
•? Moderate stenosis (30-70%) in coronary artery
•? Deferred to medical treatment based on physiologic (fractional flow reserve, coronary flow reserve, index of microvascular resistance) or radiologic (intravascular resistance with or without optical coherence tomography) evaluation.
•? Agreement obtained by participant

•? Severe renal failure (glomerular filtration rate <30 ml/min/1.73m2, hemodialysis or peritoneal dialysis)
•? Active liver disease
•? Patient taking Niacin or fibrate (if possible, patient can be enrolled to the study after stopping those medication)
•? Medical or family history of myositis, unexplained creatine kinase elevation > 3 times upper limit of normal at first visit
•? Life expectancy < 2 years (judged by investigator)
•? Coadministration of cyclosporine
•? Untreated hypothyroidism
•? Patient with poor compliance including alcohol abuse
•? History of hypersensitivity including myotoxicity for either statin or ezetimibe
•? Pregnant or breast-feeding woman
•? Other conditions inappropriate for enrollment by investigator

发起方